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Abstract 
Chemical regulation is challenged by the large number of chemicals requiring 
assessment for potential human health and environmental impacts. Current approaches 
are too resource intensive in terms of time, money and animal use to evaluate all 
chemicals under development or already on the market. The need for timely and robust 
decision making demands that regulatory toxicity testing becomes more cost-effective 
and efficient. One way to realize this goal is by being more strategic in directing testing 
resources; focusing on chemicals of highest concern, limiting testing to the most 
probable hazards, or targeting the most vulnerable species. Hypothesis driven 
Integrated Approaches to Testing and Assessment (IATA) have been proposed as 
practical solutions to such strategic testing. In parallel, the development of the Adverse 
Outcome Pathway (AOP) framework, which provides information on the causal links 
between a molecular initiating event (MIE), intermediate key events (KEs) and an 
adverse outcome (AO) of regulatory concern, offers the biological context to facilitate 
development of IATA for regulatory decision making. This manuscript summarizes 
discussions at the Workshop entitled “Advancing AOPs for Integrated Toxicology and 
Regulatory Applications” with particular focus on the role AOPs play in informing the 
development of IATA for different regulatory purposes. 
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Highlights 
 AOPs provide a mechanistic basis for IATA development 
 The elements of an AOP-informed IATA and how to integrate data are described  
 A conceptual framework based on the AOP concept is proposed 
 Examples are presented to illustrate the framework for different regulatory uses  
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1. Introduction 1 
 2 
AOPs to support IATA in regulatory decision-making 3 
Within the last decade, the global economy has witnessed a significant shift in the 4 
regulatory environment coupled with the volume and diversity of industrial chemicals 5 
being manufactured. Despite some regional differences, regulatory management in 6 
general comprises hazard identification/characterization, an exposure assessment and a 7 
risk assessment as its main steps. In some cases, the identification of hazards is prior to 8 
market approval and certain hazards e.g. carcinogenicity (C), mutagenicity (M), or 9 
reproductive (R) effects (CMRs) may lead to restrictions on use irrespective of any 10 
subsequent risk assessment. 11 
The hazard identification step is driven by a desire to identify all the hazards of potential 12 
concern and assign the appropriate hazard classification (i.e. classification & labelling 13 
requirements) regardless of the relevance of these hazards as a consequence of 14 
exposure. The hazard characterization step is often associated with extensive in vivo 15 
toxicity testing using standardized guidelines or protocols. The time, cost and animal use 16 
to generate such hazard data are significant and difficult to achieve in practice given the 17 
large number of chemicals that need to be evaluated. Furthermore, the classical in vivo 18 
testing approach is based on apical endpoints, which typically provide minimal 19 
information on the mode or mechanism of action. This limits the development and 20 
application of new in vitro assays, read-across approaches or inter-species extrapolation, 21 
all of which could facilitate an initial hazard assessment. In addition, the societal demand 22 
to use (vertebrate) animal tests only as a last resort for obtaining hazard information 23 
coupled with the increasing number of different regulatory programs worldwide calls 24 
for a re-consideration of traditional assessment strategies and incorporation of 25 
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alternative approaches. At the same time, substantial advances have been made in the 26 
use of high throughput (HT) and high content (HC) screening assays to quantify and 27 
characterize molecular and cellular responses to chemicals (Kavlock et al., 2007; Judson 28 
et al., 2014; Kleinstreuer et al., 2014). A shift towards more mechanistically-based 29 
alternative approaches represents a promising opportunity for assessing hazards of 30 
regulatory concern. To that end the Adverse Outcome Pathway (AOP) framework 31 
provides the biological context and supporting weight of evidence (WoE) to facilitate the 32 
interpretation of such alternative data. An AOP represents the existing knowledge 33 
concerning the causal linkages between the molecular initiating event (MIE) and the 34 
cascade of intermediate or key events (KEs) at the subcellular, cellular, tissue and organ 35 
level that lead to a specific adverse outcome (AO) at the individual or population level 36 
(Ankley et al., 2010; OECD, 2013). This conceptual framework enables information and 37 
data from different chemicals, different levels of biological organization, and different 38 
taxonomic domains relevant for one AOP to be assembled. Well-developed AOPs may 39 
therefore be expected to help guide identification of experimental testing (e.g. in vivo, in 40 
vitro, in chemico) and non-testing (in silico) approaches to support regulatory decision 41 
making. There is now a need for an objective framework to interpret the results from 42 
novel test methods and their prediction models in order to facilitate their application in 43 
regulatory decision making. Such a framework will conceivably consist of three main 44 
elements: the AOP itself, non-animal (alternative) test methods and in silico approaches 45 
targeting key components of the AOP, and their associated prediction models for a 46 
particular regulatory context. The synthesis and integration of these elements form the 47 
basis for developing Integrated Approaches to Testing and Assessment (IATA) that may 48 
be used in regulatory applications.  49 
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This manuscript summarises discussions from the Workshop entitled “Advancing AOPs 50 
for Integrated Toxicology and Regulatory Applications” held in Somma Lombardo, Italy 51 
on the 2-7th March, 2014 (https://aopkb.org/saop/workshops/somma.html). 52 
Specifically it captures the discussions and insights derived within the workgroup that 53 
discussed the role that AOPs can play in informing the development of IATA for 54 
regulatory purposes. The next section defines IATA and related terms. Following that, 55 
the main elements or components that make up IATA are described including 56 
considerations, (e.g. scientific confidence), that are associated with these different 57 
elements and their integration. Once the components have been defined, the overall 58 
applicability and limitations of IATA for different regulatory purposes are considered. 59 
These concepts are then illustrated by way of three examples that are supported by 60 
specific AOPs at different levels of development. A final summary considers how the 61 
proposed conceptual framework may impact different regulatory applications. 62 
 63 
2. IATA and related concepts 64 
Integrated Approaches to Testing and Assessment (IATA) are structured approaches 65 
that integrate and weigh different types of data for the purposes of performing hazard 66 
identification (i.e. the potential to cause a hazard), hazard characterization (e.g. the toxic 67 
potency) and/or safety assessment (i.e. the potential/toxicity potency related to 68 
exposure) of a chemical or group of chemicals. For the purposes of this paper, IATA will 69 
be generally referred to in a singular form to represent a specific case rather than a 70 
collective approach. An IATA should be viewed as an iterative process that includes 71 
efficiency analyses to determine whether more data, and what type of data, are required 72 
to make effective regulatory decisions while reducing reliance on animal testing. An 73 
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IATA is not a novel concept per se, indeed it has been discussed at a special OECD 74 
workshop on IATA in 2007 (OECD, 2008) and described by the US EPA as part of a FIFRA 75 
Scientific Advisory Panel document in 2011 (US EPA, 2011).  76 
An IATA initially gathers and weighs relevant existing information to derive an initial 77 
conclusion. If the existing information is insufficient to address the regulatory or safety 78 
decision under consideration, it guides the generation of new data using a hypothesis-79 
driven approach with the goal of addressing the residual uncertainty preventing a 80 
regulatory decision. The benefit of an IATA lies in the potential breadth of information 81 
that can be used in the assessment, as it may exploit both non-testing (in silico) and 82 
experimental (in vivo, in vitro and in chemico) approaches. The IATA is considered a 83 
generic approach and may encompass testing strategies such as integrated testing 84 
strategies (ITS), sequential testing strategies (STS), as well as weight of evidence (WoE) 85 
considerations (OECD, 2014). Both ITS, i.e. the fixed and structured integration and 86 
weighing of relevant information to support the final decision (Ahlers et al., 2008; 87 
Hartung et al., 2013), and STS, i.e. the fixed stepwise approach involving interim decision 88 
steps to reach a decision, represent structured and formal processes to derive a 89 
conclusion (OECD, 2014). In contrast, WoE considerations, i.e. the structured, 90 
systematic, independent and transparent review of existing and available data without 91 
use of experimental or computational efforts, aim to perform a reliable and relevant 92 
compilation of knowledge intended for a certain regulatory purpose (Balls et al., 2006; 93 
OECD, 2014). Whilst an IATA provides a structure for data integration and a means for 94 
targeting testing for particular uses, it is not necessarily framed by any mechanistic 95 
rationale. There is a growing support for using AOPs to provide such a mechanistic basis 96 
(OECD, 2013). Thus, AOP-informed IATA development may drive the development of in 97 
silico, in vitro, or in chemico approaches that are anchored in well-developed knowledge 98 
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captured within an AOP. Exposure considerations and the use of exposure assessment 99 
tools may also form an integral part of an IATA. 100 
AOPs are expected to provide insight into the biological relevance, reliability, and 101 
uncertainties associated with the results from in silico, in chemico and in vitro 102 
approaches for regulatory use. AOPs also have substantial merit in traditional 103 
assessment strategies. For instance, they can assist manufacturers and regulators to 104 
identify whether a potential hazard can be expected that justifies subsequent detailed 105 
testing. Furthermore, in the environmental hazard and risk assessment, they show great 106 
promise in the species-to-species extrapolation critical for protection of endangered 107 
species (Perkins et al., 2013). AOPs could also help to design ITS, which ideally cover the 108 
relevant key events of an AOP. AOPs are intended to provide a transparent evaluation of 109 
available evidence and relevant data, scientific confidence is envisioned to be evaluated 110 
through approaches akin to the “Bradford Hill Considerations” developed originally in 111 
epidemiology (Hill, 1965; OECD, 2013). Briefly, by examining: (1) biological 112 
concordance, (2) essentiality of Key Events, (3) concordance of empirical observation 113 
(encompasses dose response and temporal concordance and beyond), (4) consistency 114 
(among different biological contexts) and (5) analogy (consistency across chemicals), a 115 
clear statement regarding the supporting evidence for the AOP can be developed (Meek 116 
et al., 2014a, b). Depending on the outcomes for these considerations, a given AOP may 117 
differ in its level of scientific rigor and confidence, which in turn will drive its practical 118 
suitability in addressing different regulatory applications (Perkins et al., submitted; 119 
Patlewicz et al., submitted).  120 
The practical implementation of an AOP-informed IATA for a given chemical or group of 121 
chemicals considers problem formulation based on the risk management scope and 122 
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goals, the selection and evaluation of suitable AOPs to inform the IATA and existing 123 
information that is available for the chemical(s) of interest. All these considerations will 124 
influence the makeup of an IATA in terms of the different types of testing (e.g. in 125 
chemico, in vitro and in vivo), non-testing (e.g. in silico), or data integration approaches 126 
(e.g. ITS, STS, WoE or other IATA strategies) that can be exploited (Figure 1).  Figure 1 127 
outlines a proposed framework to guide how existing information (e.g. hazard and 128 
exposure information) needs to be evaluated and what new data, if any, needs to be 129 
generated, so that the IATA can lead to a regulatory decision.  130 
 131 
 132 
Figure 1. Conceptual framework for an AOP-informed IATA to support regulatory 133 
decisions. The framework is driven by the problem formulation, which involves a 134 
consideration of the risk management scope, the data requirements and the level of 135 
acceptable uncertainty associated with the decision being made. The regulatory 136 
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application will also provide an indication of the level of AOP confidence, ideally needed. 137 
The framework, which comprises different elements (testing and non-testing approaches, 138 
etc.), will evaluate the existing information that is available for the chemical(s) of interest 139 
(a), the type of information that might be required as defined by the AOP itself (b), and 140 
other relevant information that is pertinent in making a regulatory decision (c). If the 141 
outcome generated based on the framework is of sufficient confidence for the regulatory 142 
purpose of interest, no further action is warranted. If the outcome derived from the 143 
framework is of insufficient confidence, then additional data might need to be generated 144 
through new testing and assessment. The new information derived will then be passed back 145 
into the framework for re-evaluation. Indeed a decision outcome could result in more 146 
thorough regulatory follow up or implementation of measures to reduce use and/or 147 
exposure. Any new information generated will also be used to augment the corresponding 148 
AOP. 149 
 150 
3. Elements for developing AOP-informed IATA  151 
Non-testing and testing approaches as well as data integration strategies form the 152 
elements or building blocks that are necessary to derive IATA. These elements are 153 
described in more detail in terms of the applicability and limitations in the following 154 
sections.  155 
3.1 Non-testing approaches 156 
Non-testing or in silico approaches serve two functions within an IATA, they either 157 
provide a way to organize existing information or they are used to make predictions of 158 
molecular initiating events (MIE) or other key events (KEs) as defined in an associated 159 
AOP. The breadth of non-testing approaches is extensive. They range from the search 160 
and retrieval of existing data, to the identification of structural fragments to indicate 161 
activity and assist grouping (e.g. structure-activity relationships (SARs), read-across), to 162 
quantitative models (e.g. quantitative structure-activity relationships (QSARs). Some of 163 
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these SARs or QSARs may be housed in software tools known as expert systems for ease 164 
of use. A summary of non-testing approaches that may be useful in the development of 165 
IATA are described in more detail in Cronin and Madden, (2010).  166 
Within IATA, non-testing approaches will most likely be exploited to characterize the 167 
MIE within AOPs either qualitatively or quantitatively (Table 1). A number of different 168 
types of MIEs, and thus AOPs, may be identified for a given IATA in order to generate 169 
sufficient information for the decision to be made.  170 
 171 
Table 1. Examples of MIEs within AOPs that may be relevant to IATA endpoints derived 172 
from non-testing approaches. 173 
MIE Effect Examples of In Silico Tool(s)  
Unspecific – no 
definable single 
molecular site of 
action 
General accumulation 
in cellular membranes 
leading to e.g. 
narcosis, basal 
cytotoxicity etc. 
Classification schemes e.g. Verhaar 
implemented in the OECD QSAR 
Toolbox or Toxtree. QSARs based on 
hydrophobicity.   
Non-specific 
covalent binding 
(and formation of 
radicals) 
Irreversible binding to 
cellular protein and 
/or DNA which may 
lead to a variety of 
effects; e.g. fibrosis 
OECD QSAR Toolbox profilers for 
protein and DNA binding. Quantum 
chemical calculations.  
Redox cycling 
leading to disruption 
of specific pathways 
Mitochondrial toxicity Structural alerts e.g. Nelms et al., 
2014 
Receptor mediated 
effects on signalling 
pathways 
A wide variety of 
acute and non-lethal 
effects e.g. estrogen 
receptor binding 
3-D molecular modelling. 
Toxicophores / alerts e.g. EPA ER 
Binding Expert System as encoded 
in the OECD QSAR Toolbox, DART 
system (Wu et al., 2014) 
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Physical effects Skin corrosion  Structural alerts, physicochemical 
properties e.g. pH 
Unknown or very 
poorly defined MIE 
Idiosyncratic drug 
toxicity  
Structural alerts  
 174 
3.1.1 Confidence Factors for In Silico Models in IATA 175 
Assuring scientific confidence in the validity of in silico models and their outcomes are 176 
key considerations for their application. For (Q)SARs, the OECD has developed 177 
validation principles which provide a framework for assuring the scientific validity 178 
(relevance and reliability) of a (Q)SAR model (OECD, 2004; 2007). The (Q)SAR model 179 
reliability is a relative concept, depending on the context in which the model is applied; 180 
meeting each and all of the OECD principles is not necessarily warranted. It is worth 181 
noting that the OECD principles only focus on the scientific validity of a given (Q)SAR 182 
model, and not on the prediction it generates. The adequacy of a (Q)SAR result for a 183 
given compound also needs to be considered before use. In the context of the European 184 
Regulation for registration, evaluation, authorisation and restriction of chemicals 185 
(REACH) (EC, 2006; ECHA, 2008) the following specific conditions are considered when 186 
evaluating in silico models: 187 
1. the estimate should be generated by a valid (relevant and reliable) model; 188 
2. the model should be applicable to the chemical of interest with the necessary 189 
level of reliability; 190 
3. the model endpoint should be relevant for the regulatory purpose. 191 
 192 
Whilst these were outlined specifically for REACH, the conditions could be conceivably 193 
adapted to address other regulatory purposes. 194 
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For chemical categorization (OECD, 2014) (e.g. read-across), no such principles have 195 
been formalized. Systematic frameworks to aid in the evaluation of read-across and 196 
identify associated uncertainties are in development by European Chemicals Agency 197 
(ECHA) (known as the Read-Across Assessment Framework (RAAF)) as well as by 198 
Industry (Blackburn and Stuard, 2014). To date these frameworks do not specifically 199 
consider the role of AOPs or how alternative data characterizing MIEs or other KEs may 200 
be conceivably used to address uncertainties. Work underway within the SEURAT 201 
program (ChemWatch, 2014 – see: http://chemicalwatch.com/19594/seurat-1-homes-202 
in-on-test-chemicals-for-read-across) and independently by DECO-2, a Cefic-LRI AIMT-4 203 
project (Patlewicz et al., in preparation) are both aiming to investigate the feasibility of 204 
enhancing read-across by using the AOP concept. 205 
It is noteworthy to mention that there will be clear instances when in silico approaches 206 
will not provide meaningful information in the context of an IATA, for example if there is 207 
no direct linkage to the MIE because the MIE is unknown or ill-defined. Predictions from 208 
in silico approaches will also be inappropriate, when the target substance is outside of 209 
the applicability domain of the model. 210 
 211 
3.2 Testing approaches 212 
There are many testing approaches that can form key elements within an IATA – from in 213 
chemico, in vitro to in vivo experimental efforts. Testing elements such as 214 
toxicogenomics, high content/high-throughput screening (HC/HT) in particular will play 215 
a crucial role in shifting IATA away from a reliance on in vivo information addressing one 216 
or multiple adverse outcomes. 217 
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 218 
3.2.1 In chemico tests 219 
Biological effects of chemicals can be provoked by an initial covalent modification of a 220 
biological macromolecule. The covalent modification of DNA leading to mutagenesis or 221 
the reaction with immunoproteins resulting in immunosuppression represent 222 
prominent examples (Cronin et al., 2009). In chemico tests are experimental 223 
measurements that address these covalent modifications without involving biological 224 
organisms (reviewed in Schwöbel et al., 2011). These assays are usually used to identify, 225 
and in some cases estimate, the intrinsic reactivity of substances to a specific biological 226 
target and in that respect are best suited to target the MIE within an AOP. Most in 227 
chemico tests relevant to toxicity prediction have investigated the reaction of an 228 
electrophilic molecule (normally assumed to be the toxicant) with a model nucleophile 229 
(representing a surrogate for the target biological macromolecule) (e.g. Roberts et al., 230 
2008; Aptula and Roberts, 2006; Schultz et al; 2005; Thaens et al., 2012). Also included 231 
in this type of data could be the assessment of oxidizing behavior and the role of other 232 
reactive species (nucleophiles, reactive oxygen species, radicals) principally amenable to 233 
in chemico testing (Cronin et al., 2009).   234 
 235 
3.2.2 In vitro and alternative test systems 236 
Cellular in vitro systems, lower vertebrate embryos and invertebrates are proposed and 237 
used as alternative test system to indicate toxic potential to various organisms. Relevant 238 
information on the toxic potential of a chemical can be obtained via e.g. comparison of 239 
the toxicity to baseline toxicity as an indicator of a non-narcotic or specific mode of 240 
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action (Escher and Schwarzenbach, 2002). By including appropriate endpoints it is 241 
possible to target MIEs or KEs relevant for an AOP-informed assessment.  Extrapolations 242 
from alternative test systems, however, have to consider that the toxicokinetic 243 
properties may greatly differ and result in deviating effect concentrations between e.g. in 244 
vitro and in vivo tests. Fish/amphibian embryos or invertebrates – despite their 245 
evolutionary distance to e.g. mammalians or other vertebrate classes – may provide in 246 
some cases a higher predictive capacity than in vitro systems given that they 247 
represent/accommodate the complexity of a whole organism (Perkins et al., 2013). 248 
 249 
3.2.3 High throughput screening assays 250 
High throughput screening assays (HT) comprise in chemico and certain in vitro test 251 
methods such as receptor binding or receptor transactivation assays (Romanov et al., 252 
2008), cellular reporter assays (Romanov et al., 2008; Kleinstreuer et al., 2014), assays 253 
using invertebrate (e.g. C. elegans, Drosophila, algae, crustaceans, see Perkins et al., 254 
2013) or fish embryos (Truong et al., 2014). Toxicogenomic (transcriptomics, 255 
proteomics, and metabolomics), utilizing non-biased screening approaches may play a 256 
more important role in the future within IATA, since they allow more detailed insights 257 
into mechanisms of action and can be applied to survey the breadth of 258 
molecular/cellular effects relevant for a wide variety of AOPs (Garcia-Reyero et al., 259 
2014a,b).  260 
Assays targeted towards MIEs, can be very specific for a distinct target (e.g., receptor, 261 
enzyme) that leads to an AO. This specificity will also provide the chemical structure and 262 
bioactivity data needed to foster development of in silico models (as described in section 263 
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3.1). Assays that target downstream KEs such as more generic stress responses 264 
(Simmons et al., 2009) may not have this specificity, but may provide an approach to 265 
integrate multiple MIEs (Miller et al., 2009). More importantly, analysis of downstream 266 
KEs provide the opportunity to predict an AO even in cases where the precise MIE is not 267 
known or is not fully understood. Table 2 presents several examples of alternative 268 
experimental testing approaches that may be relevant to predict AOs within an IATA.  269 
 270 
Table 2. Summary and examples of the different types of experimental testing 271 
approaches in AOP-informed IATAs.  272 
Approach Usage AOP 
target 
Example(s) of 
HT/HC 
compatible 
assays  
Adverse outcome 
In chemico Indicate 
reactivity or 
covalent 
interaction 
with a 
biomolecule  
MIE GSH (Schultz et 
al., 2005);dNTP 
adduct 
formation (Zhao 
et al. 2002) 
Unspecific (excess 
toxicity), 
genotoxicity/mutagenicity, 
immunosuppression, skin 
sensitization 
In vitro 
(cellular) 
Confirm 
toxicity 
pathway 
Confirm the 
(absence of) 
need for 
higher-tier 
testing 
Can be 
HT/HC 
compatible 
MIE, KE Cell lines, 
transactivation 
and reporter cell 
assays, 
subcellular 
assays, e.g. HTS 
assays for 
endocrine 
disruption (Cox 
et al., 2014, 
Murk et al., 
2013)  
Through targeting specific 
toxicity pathways, a wide 
range of AOs can be 
targeted (Bhattacharya et 
al. 2011), e.g. for 
endocrine disruption 
sexual development, 
reproductive disorders. 
Many different endpoints 
are possible through 
targeting specific toxicity 
pathways. 
Invertebrates Replace 
(vertebrate) 
MIE, KE C. elegans 
(Leung et al. 
e.g. acute toxicity, 
developmental toxicity, 
neurotoxicity, 
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animal tests 2008),  
 
genotoxicity,  
Fish or 
amphibian 
embryos 
Replace 
(adult 
vertebrate) 
animal tests 
MIE, KE D. rerio embryos 
(Truong et al., 
2014) 
Acute and chronic fish 
toxicity, hepatoxicity 
neurotoxicity, 
teratogenicity, endocrine 
disruption (reviewed in 
Scholz et al., 2013a,b), 
GSH: Reduced glutathion, dNTP: Deoxyribonucleotide triphosphate, HT/HC: High-throughput/High-273 
content. 274 
3.2.4 Confidence factors and limitations for testing approaches in IATA 275 
The use of alternative testing approaches provide higher confidence when they are 276 
scientifically and technically valid for use. Validation of  alternative assays in particular 277 
HT/HC assays has been subject of several publications such as Judson et al. (2013), 278 
Hartung et al. (2013) and Patlewicz et al. (2013). In the latter scientific confidence was 279 
discussed in the context of the existing validation frameworks for (Q)SARs and 280 
biomarkers (Institute of Medicine, 2010). In Cox et al. (2014), a scientific confidence 281 
framework was proposed comprising three inter-related elements to facilitate the 282 
systematic, transparent and objective evaluation and documentation of HT/HC assays 283 
and their associated prediction models. The elements comprise analytical validation, 284 
qualification and utilization. Analytical validation would entail an assessment of the 285 
biological basis and analytical performance of the assays. This would involve a 286 
consideration of what events within the AOP the assay(s) were mapped to – whether 287 
they target the MIE or other downstream KEs. The applicability domain of the assay in 288 
terms of the chemical coverage and the typical performance statistics – sensitivity, 289 
specificity, accuracy, would be considered as well. The qualification step would involve 290 
an assessment of the associated prediction models derived from such assays and 291 
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utilization would consider the intended regulatory application based on the previous 2 292 
steps.  293 
Even when assays have been scientifically and technically validated, they may exhibit 294 
certain limitations. Most assays do not consider the impact of potential metabolic 295 
transformation, which can lead to reduced sensitivity (in case of in vivo metabolic 296 
activation) or to a high number of false positives (in case of in vivo inactivation) or false 297 
negatives (in case of in vivo bioactivation).  Furthermore, certain compounds are difficult 298 
or impossible to test using in vitro systems, for example due to their poor solubility in 299 
the culture medium, aggregation potential, volatility, or partitioning behavior (tendency 300 
to adsorb onto plastic). In such cases in silico methods could provide a more appropriate 301 
approach (Zaldivar et al, 2010, 2011). 302 
 303 
3.3 Data-integration strategies 304 
Whilst there has been a tendency to define one “definitive” test for hazard assessment in 305 
the past, increasingly the need for more than one piece of evidence for hazard 306 
assessment has become evident. This need is fundamental in both the AOP concept and 307 
the AOP-informed IATA. Therefore, data integration strategies are needed to integrate in 308 
silico, in chemico, in vitro, in vivo, and available epidemiological or clinical data which  309 
1. Allow for the combination of low-cost (sensitive) screening assays with more 310 
sophisticated (specific) confirmatory assays. 311 
2. Consider the incomplete coverage of one assay in the chemical universe 312 
(applicability domain), severity classes or modes of action. 313 
3. Compensate for the insufficient reliability of a single test. 314 
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4. Combine kinetic and exposure information, with (quantitative) in vitro to in 315 
vivo extrapolation.  316 
Testing and non-testing outcomes can be manually integrated together to derive an 317 
outcome for specific regulatory purposes. This is relatively straightforward for a simple 318 
linear AOP with a limited number of KEs, such as skin sensitization (OECD, 2012a,b). As 319 
more AOPs are developed, and KEs are identified that cut across different AOPs into 320 
networks of interlinked AOPs, the complexity of data integration supporting an IATA will 321 
increase. Manual integration of a myriad of KEs may not be feasible to do. Moreover, 322 
some of the assay outcomes or prediction models derived may require interpretation, a 323 
translation step to convert the raw test outcome into a form that addresses the 324 
information need for the regulatory purpose under consideration (see Weinberg, 1972 325 
for detailed discussion).  Note this interpretation step is not specific to IATA, but as the 326 
complexity of IATA increases, more formalized systematic and transparent translation 327 
approaches will be required. Integration of many information sources can be addressed 328 
in different ways from: 329 
1. Battery approaches, i.e. all results are collected and then interpreted 330 
2. Sequential / tiered approach, i.e. in a given sequence results are 331 
collected stopping when sufficient information is available through to 332 
3. Result-driven further testing, e.g. determination of next most valuable 333 
test or branching of test strategies depending on previous test results 334 
(prioritization). 335 
21 
 
Integration of results derived from these information sources in turn occurs on different 336 
levels, from the raw data level to the summary (categorical) level where certain 337 
information is lost. Examples of data integration approaches include: 338 
1. Boolean AND / OR / NOT combinations of categorized results (e.g. overall call 339 
is denoted as positive if any of the test outcomes are positive) 340 
2. Scoring approaches (e.g. various tests contributing to an overall score) 341 
3. Decision trees (typically sequential with branching) 342 
4. Deterministic, i.e. a point of departure for assessments is derived (e.g. lowest 343 
active concentration) possibly combined with assessment factors to derive a 344 
threshold value 345 
5. Probabilistic, i.e. probabilities are assigned as a function of different 346 
information leading typically to distributions of probabilities / uncertainties 347 
6. Prediction based on machine learnings (e.g. PCA, random forest, multiple 348 
regression) applied to a training set of compounds 349 
IATA does extend beyond hazard information and will often also include kinetics and 350 
exposure data, which in turn augments the complexity of the data integration 351 
approaches applied. At this stage, no general guidance can be proposed, although it is 352 
envisaged that a learning-by-doing is necessary and the advantages (and possible 353 
disadvantages) of formally integrated data will emerge and can be resolved. 354 
 355 
4. Applicability of AOP-informed IATA for regulatory purposes 356 
Any non-standard approach needs to be fit for purpose whether it will be used for 357 
prioritization, hazard identification, classification & labelling and/or risk assessment. 358 
This is true for IATA as a whole, as well as the respective IATA elements themselves; the 359 
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latter of which have already been discussed in the previous sections. Specific criteria to 360 
define fitness for specific regulatory applications have not been defined but guiding 361 
principles are being proposed. Becker et al. (2014) outlined a scientific confidence 362 
framework first proposed for HT/HC screening assays (Patlewicz et al., 2013) and their 363 
prediction models (Cox et al., 2014) but adapted it to help in the evaluation of AOPs for 364 
different purposes including IATA. Specific guidance for the assessment of IATA is not 365 
currently available but recent initiatives taken up by the OECD Task Force for Hazard 366 
Assessment (TFHA) are aiming to develop general principles for the evaluation and 367 
documentation of IATA using skin sensitization as an initial case study (Worth and 368 
Patlewicz, submitted). The initial principles proposed are framed by a clear identification 369 
of the regulatory requirement as well as the applicability domain of the IATA itself:  370 
a) define the endpoint of regulatory concern being assessed;  371 
b) define the purpose/application for which the IATA is proposed; 372 
c) describe the rationale, including mechanistic basis (e.g. AOP), according to which 373 
the IATA is constructed; 374 
d) describe the individual information sources constituting the IATA; 375 
e) characterize the predictive performance and applicability domain of the IATA, or 376 
IATA subcomponent(s) that can be expressed as a prediction model(s). 377 
 378 
5. Examples of AOP-informed IATAs in regulatory decision-making 379 
There are many potential regulatory applications for IATA. In this section, we highlight 380 
three case study examples, which target different regulatory scenarios and hence are 381 
characterized by differing levels of scientific confidence. 382 
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 383 
5.1. Identification of chemicals disrupting estrogen, androgen, and thyroid 384 
hormone pathways  385 
Endocrine disruption, particularly disruption of estrogen, androgen and thyroid 386 
pathways, is considered as an endpoint of high regulatory concern, given the potential 387 
adverse impact on human and environmental health, particularly sexual differentiation, 388 
reproduction and population development. AOPs linked to endocrine disruption of these 389 
three hormonal pathways represent examples where links between the MIE and KEs and 390 
the final AO have been reasonably established (Ankley et al., 2005; Miller et al., 2009; 391 
Volz et al., 2011). The OECD has already provided a conceptual framework describing 392 
the assays that would be available to target the different MIE and KE for endocrine 393 
disruption (OECD 2012c). Recent suggestions for developing scientific criteria for 394 
identification of an endocrine disrupting chemical (EDC) also conform to the principle of 395 
providing evidence of causality between mechanistic information (e.g. KEs) and AOs for 396 
endocrine disruption (Munn and Goumenou, 2013). Principally there is no single AOP 397 
for endocrine disruption. Depending on the targeted hormonal pathway or whether it is 398 
applied in the environmental or human health context, multiple AOPs could be defined. 399 
However, they share great commonalities at the different levels of biological complexity 400 
and are therefore described here.   401 
Table 3. Examples of MIEs and KEs relevant for different levels of the AOPs for endocrine 402 
disruption. Given the large number of assays available for the different MIEs, KEs, and 403 
AOs, only selected examples are presented. For further assays descriptions refer to 404 
OECD (2012c). 405 
AOP level (MIE Description Level of Test/Non test method 
24 
 
and KE not in 
sequential 
order) 
(examples) biological 
organization 
examples 
MIE1 Hormone 
receptor 
binding and 
activation 
Molecular level Receptor-ligand binding assays 
(Tollefsen and Nilsen, 2008); 
Transactivation assays (Legler 
et al., 1999); 
QSARs for hormone receptor 
binding  (Lo Piparo and Worth, 
2010; Novic and Vracko, 2010) 
MIE2 Interference 
with hormone 
synthesis 
Molecular level Steroidogenesis in vitro (OECD 
TG 456); 
In vitro assays for induction 
and inhibition of enzymes for 
TH metabolism (Murk et al., 
2013); 
Zebrafish embryo assay for 
disruption of thyroid gland 
function (Raldua, 2009) 
 
KE 1 Cell 
proliferation 
Cellular MCF7 cell proliferation assay 
(Körner et al., 1998) 
KE 2 Increased 
vitellogenin 
Cellular In vitro fish hepatocyte 
vitellogenin production 
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production (Tollefsen et al., 2008) 
KE3 Proliferation of 
uterus 
Metamorphosis 
Organ Uterotrophic assay (OECD TG 
440) 
Amphibian metamorphosis 
assay (OECD TG 231) 
KE4 Vitellogenin 
induction, 2nd 
sex 
characteristics, 
fecundity, 
gonad 
development 
Organ 
Organism 
Fish Reproductive Screening 
Assay (OECD TG 229) 
 
AO Reproduction Population Reproductive toxicity studies 
Fish full life cycle assays (TG 
415, 443) 
 406 
   In the US, the Endocrine Disruption Screening Program (EDSP) was established 407 
in an effort to identify substances with the potential to interact with components of the 408 
endocrine system. The Program comprises two Tiers; Tier 1 consists of a battery of in 409 
vitro and in vivo assays that are intended to determine the potential of a chemical to 410 
interact with the estrogen (E), androgen (A), or thyroid (T) hormone pathways whereas 411 
Tier 2 comprises multigenerational reproductive and developmental toxicity tests in 412 
several species to determine whether a substance can cause adverse effects resulting 413 
from effects on the E, A, or T pathways. In Tier 2, the tests to be run are selected by a 414 
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WoE evaluation of Tier 1 results. The Tier 1 battery itself is expensive, time consuming 415 
and does not lend itself to the assessment of large numbers of chemicals (each Tier 1 416 
costs of the order of 1 million US dollars).  Furthermore, it still relies to a large extent on 417 
in vivo assays.  Hence, more cost-efficient processes relying on in silico (QSAR and Expert 418 
Systems) and HT screening data for prioritizing large numbers of chemicals for hazard 419 
assessment purposes are being developed (Figure S1, supplementary information 420 
outlines the use of the framework for prioritizing substances for their potential E, A and 421 
T effects). When coupled with exposure predictions (from ADME and exposure models), 422 
such a combination of non-testing and resource-efficient testing approaches could 423 
provide sufficient confidence in prioritization decisions for subsequent testing 424 
requirements.  The EDSP represents an opportunity where relevant HTS assays can be 425 
mapped to associated AOPs that are already well understood (e.g. Schmieder et al., 2003; 426 
Crofton and Zoeller et al., 2005) and where confidence in the HTS predictive power for 427 
higher levels of the AOP are well established. 428 
While the goal of the US EDSP and application of corresponding HTS assays is clearly one 429 
of prioritization and directing of testing, there is also scope to apply a tiered approach 430 
for defined testing schemes such as required by European Union regulation. Substances 431 
with endocrine disrupting capacity are conditionally exempted from exposure criteria, 432 
i.e. higher tier assays for these compounds are required also at lower production 433 
volumes. Similarly, Tier 1 in vivo assays to analyze the endocrine disruption potential are 434 
required in environmental hazard assessment for the regulation of pesticides, biocides 435 
and pharmaceuticals (Scholz et al., 2013a, b). It is however, not yet clear how the 436 
endocrine disrupting potency will be identified but HT assays may provide a cost-437 
effective and reliable approach. 438 
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HT screening assays for determination of interference with hormone production, 439 
hormone receptor binding and activation are currently available for a number of 440 
hormone pathways. Of these, assays to target interference with the estrogen pathway 441 
seems to be best developed with HTS methods for steroidogenesis and aromatase 442 
inhibition (Villeneuve et al., 2007; Vinggaard et al., 2000), estrogen receptor (ER) 443 
binding and activation (Legler et al., 1999; Tollefsen and Nilsen; 2008; Tollefsen et al., 444 
2008) and in silico (QSARs and docking models) for interaction with the ER (Schmieder 445 
et al., 2003; Mombelli, 2012). A similar suite of bioassays exists for androgen signaling 446 
pathways, although the role of androgen agonists or antagonists in endocrine disruption 447 
is not as well developed. Nevertheless, assays such as a transcriptional activation assay 448 
for the detection of the androgenic and anti-androgenic activity of chemicals have been 449 
developed to support the assessment of disruption of the androgen axis (Rostkowski et 450 
al., 2011).  HT assays for detecting thyroid receptor agonists and antagonists also exist 451 
(Murk et al., 2013), however, the majority of thyroid disruptors act via a variety of MIEs 452 
that alter cellular TH signaling pathways via modulation of the TH levels. Thus, for 453 
thyroid disrupting compounds the most relevant KE with respect to AO is the reduction 454 
of thyroid hormone synthesis and homeostasis (Capen, 1997; Crofton, 2008). 455 
Appropriate thyroid hormone-relevant assays are missing for many of the targets, and 456 
development of appropriate assays that cover relevant MIEs and KEs are strongly 457 
needed (Murk et al., 2013). As an interim approach, TR transcription assays such as 458 
ToxCast and Tox21-TR assays can be applied. Assays of fish embryos targeting reduced 459 
T4-levels (Thienpoint et al., 2011; Opitz et al., 2012) can be employed to identify 460 
goitrogens. Despite the remaining high uncertainty for thyroid hormone disruption, a 461 
significant reduction of higher tier testing could be achieved by including exposure 462 
modelling into the screening approach. Wambaugh et al (2013) have developed a high-463 
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throughput exposure model that uses data on production and use of chemicals, in 464 
combination with a Bayesian statistical approach to describe the degree of uncertainty, 465 
to provide exposure estimates for thousands of chemicals.  Combining this with hazard 466 
data allows for a rapid estimate of margins of exposure and prioritization of further 467 
testing using both exposure and hazard data.  Whilst the IATA framework has been 468 
illustrated for prioritization per se, it could be refined for other purposes such as 469 
classification and labelling, or hazard assessment both of which would be pertinent for 470 
registration of chemicals in Europe.  471 
 472 
5.2 Skin sensitization 473 
Skin sensitization has been well studied over many decades. The chemical and biological 474 
pathway driving the induction and elicitation of allergic contact dermatitis is relatively 475 
well understood (see Lepoittevin J-P et al, 1997; Smith Pease CK, 2003, Adler et al, 2011) 476 
and this knowledge has helped shape the development of alternative non-animal test 477 
methods.  Most recently the knowledge has been structured and documented in an AOP 478 
construct and published by the OECD (OECD, 2012a, b). The OECD documentation for 479 
this AOP summarizes the scientific evidence and assesses the overall WoE supporting 480 
the AOP.  There is strong evidence for the qualitative sequence of events from the MIE to 481 
AO.  Indeed empirical evidence from various elements of the AOP has value in assessing 482 
the potential of a chemical to be a skin sensitizer but, with few exceptions, it is 483 
insufficient to predict the relative potency of a chemical. As such, animal methods, in 484 
particular the Local Lymph Node Assay (LLNA) are at present still needed to provide a 485 
quantitative measure of relative sensitizing potency, which is critical for risk assessment 486 
applications.  487 
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In order for the AOP for skin sensitization to be applied in practice, available test/non 488 
test approaches that characterize each of the KEs need to be mapped to the AOP. This 489 
mapping provides a perspective of what practical testing/non testing strategies could be 490 
derived as IATA. For skin sensitization, there has been considerable progress in 491 
developing specific test methods that target MIEs and many of the KEs relevant for the 492 
AO (see Table 4 for examples of appropriate assays). 493 
 494 
Table 4. A summary of in silico and experimental testing approaches targeting MIEs and 495 
KEs of skin sensitization.  496 
AOP level Description Level of biological 
organization 
Test/Non test 
method 
Dermal exposure  Dermal metabolism, 
epidermal 
disposition 
Chemical structure 
& properties 
(Q)SARs 
 MIE Covalent binding 
between 
electrophile and 
skin protein 
Molecular level DRPA (Gerberick et 
al., 2004; 2007), 
GSH depletion assay 
(Schultz et al., 
2005), QSARs/read-
across 
KE 1 Activation of 
inflammatory 
cytokines 
Cellular response KeratinoSens™ 
(Emter et al., 2010, 
2013) read-across 
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KE 2 Maturation and 
mobilization of 
dendritic cells 
Cellular response MUSST (Python et 
al., 2007), h-CLAT 
(Sakaguchi et al., 
2007), read-across 
KE 3 T-cell proliferation Organ response LLNA (OECD Test 
Guideline (TG) 429), 
QMM, read-across 
Adverse Outcome 
(AO) 
Allergic contact 
dermatitis 
Organism response GPMT (OECD TG 
406); HRIPT 
DRPA: Direct Peptide Reactivity Assay, GSH: Reduced glutathione, MUSST: MYELOID U937 SKIN 497 
SENSITIZATION TEST, h-CLAT: human Cell Line Activation Test, LLNA: Mouse Local lymph Node 498 
Assay, QMM: quantitative mechanistic model, GPMT: Guinea Pig Maximization Test, HRIPT: 499 
Human Repeat Insult Patch Test 500 
 501 
A specific framework for the assessment of skin sensitization potential was adapted 502 
from Figure 1 (shown in Figure S2 of the supplementary information). In applying the 503 
framework, two outcomes can be envisaged – either the evaluation of the model/assay 504 
outcomes will result in a consistent profile enabling an assessment of skin sensitization 505 
hazard to be made (i.e. the substance is (not) a skin sensitizer with high confidence) or 506 
the outcomes are insufficient to conclude with any great certainty that the substance is 507 
(not) as skin sensitizer. The latter could be due to inadequacies in the model/assay 508 
domains of applicability either on the basis of the underlying training sets or due to 509 
technical limitations in the assays themselves (volatility, solubility, metabolic 510 
competence). These insufficiencies however inform the development or refinement of 511 
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new test assays or refinement/extension of the in silico models. Any new information 512 
then generated can be passed back to refine and improve the original AOP for 513 
sensitization. A more detailed example for this IATA for skin sensitization has been 514 
discussed in a separate manuscript (see Patlewicz et al, 2014). 515 
 516 
5.3 AChE inhibition leading to lethality 517 
Organophosphate and carbamate insecticides, which are widely used for agricultural 518 
and residential purposes, have frequently been reported to cause toxicity to organisms 519 
ranging from invertebrates to vertebrates and mammals (McHenery et al., 1997; Fulton 520 
and Key, 2001). The toxicity of these compounds is mainly due to the selective inhibition 521 
of acetylcholinesterase (AChE), leading to accumulation of acetylcholine (ACh) in the 522 
synaptic cleft, subsequent overstimulation, and the disruption of nerve impulses 523 
ultimately leading to ataxia, central respiratory paralysis, seizures, coma and death 524 
(Costa, 2006, Bradbury et al. 2008). The well-developed knowledge on how these 525 
chemicals cause lethality has led to the development of an AOP for acetylcholinesterase 526 
inhibition leading to acute mortality (Russom et al., 2014). This AOP is characterized by 527 
a clear mechanistic understanding of the MIE, KEs and AOs (Table 5) for a number of 528 
species (Russom et al., 2014). The available information on relevant chemical structures, 529 
the overall weight of evidence and the broad taxonomic applicability domain of this AOP 530 
are of particular value to inform and provide input to IATAs, particularly for cross-531 
species extrapolations.    532 
 533 
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Table 5. A summary of in silico and experimental testing approaches relevant for 534 
different levels of the AOP – Acetylcholine esterase (AchE) inhibition leading to lethality 535 
(Russom, et al., 2014). References represent examples only.  See Russom, et al. (2014) 536 
for a more extensive review of the literature supporting this AOP. 537 
AOP level Description Level of 
biological 
organization 
Test/Non test method 
MIE Inhibition of AchE 
activity. Inhibition 
caused by non-
reversible or 
reversible inhibition.   
Molecular level QSARs/read-across 
Inhibition of AchE activity 
(in vitro) (Garcia-Reyero et 
al., 2014b; Holth and 
Tollefsen, 2012) 
KE1 Accumulation of 
acetylcholine (ACh) 
in the synaptic cleft 
Cellular level No direct test-method 
available;  biological 
plausibility well 
established; many studies 
linking MIE with 
downstream KEs & AOs 
across a variety of species 
(Bianco et al., 2013); Brain 
ACh levels can serve as a 
surrogate biomarker for 
associated KEs (Kobayash 
et al., 1985); 
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KE2 Excitatory responses 
in muscle and brain 
Organ level Electrophysiology in 
isolated neurons (Oyama, 
et al., 1989); Contractile 
response in muscle 
(Kobayash et al., 1994); 
Altered response in brain 
(biological plausibility well 
established) 
AO Neurotoxic 
symptomology 
(increased 
respiration, 
bradycardia, 
seizures) leading to 
death  
Organism Respiratory/cardiovascular 
responses (McKim, et al., 
1987); Altered photomotor 
or locomotor response 
(Kokel et al. 2010, Irons et 
al. 2010, Garcia-Reyero et 
al 2014b);  
AO Population decline Population Inferred based on 
measured effects on 
mortality (Barata et al., 
2004) and feeding behavior 
(Hunt, et al., 1991)  
   538 
Since Acetylcholine esterase (AchE) inhibition is a well-established AOP, it can support a 539 
variety of regulatory uses. The WoE supporting this AOP is strong (Russom, et al., 2014), 540 
and there is extensive toxicity data for a number of chemicals in a variety of species that 541 
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is consistent with mechanistic knowledge assembled in the AOP 542 
(http://www.epa.gov/ecotox/). Information from in vitro results could potentially be 543 
used under certain circumstances, but the use of in vitro AChE inhibition alone may not 544 
be sufficient (Knudsen et al., 2011) possibly due to lack of these assays accounting for 545 
bioactivation of certain chemicals such as Diazinon by metabolism (Aylward et al., 2011) 546 
or mitigation of effects by metabolic degradation such as observed for malathion (de 547 
Bruijn and Hermens, 1993). In silico approaches might be sufficient for some uses 548 
(Fukuto et al., 1990; El Yazal et al., 2001; Wong et al., 2012), but should be used with 549 
caution particularly in cases where metabolic activation is required (de Bruijin and 550 
Hermens, 1993). Extensive in vivo data exist with reasonable concordance seen between 551 
sequence similarity among AChE enzymes and in vivo activity across non-vertebrate 552 
species (Russom, 2014). For animals, including humans, determination of AchE 553 
inhibition in both the central and peripheral nervous systems are considered crucial for 554 
a thorough evaluation of potential hazard 555 
(http://www.epa.gov/pesticides/trac/science/cholin.pdf). However, blood 556 
cholinesterase inhibition is accepted as a surrogate parameter in humans, when data for 557 
AchE inhibition in peripheral and central nervous system are not available. 558 
Recommendations on surrogate parameters in wildlife have currently not been 559 
developed sufficiently to support a WoE approach to identify potential hazard.  560 
 561 
To illustrate how this AOP could be used in IATA, consider the classification of a 562 
pesticide known to act via AChE inhibition as a potential application. A particular 563 
concern in this case is the biological impact on non-target organisms (see Figure S3 in 564 
supplementary information). If this is a crop use that is expected to result in minimal 565 
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exposure through either application or ingestion, the species of concern might be 566 
restricted to non-target organisms that would be exposed during the application or via 567 
interactions with the treated crops and possibly aquatic organisms from run off 568 
following application.  Demonstration of low level of exposure in combination with low 569 
sensitivity for AchE in vertebrates, would be expected to limit potential hazards to non-570 
target invertebrates.  If toxicity data from the target species (e.g. insects for use of 571 
insecticides) exist, hazard assessment could be facilitated by sequence alignments to 572 
predict cross-species susceptibility to non-target species where exposure is considered 573 
relevant (Lalone et al., 2013; Russom et al., 2014).  Documentation of potential risk 574 
scenarios (e.g. small margin of safety between exposure and potential effects) based on 575 
the non-testing approaches proposed herein, may lead to a decision to generate 576 
additional testing data using in vivo studies with the appropriate species or relevant 577 
surrogate species in cases where testing is not feasible (e.g. endangered species, lack of 578 
appropriate laboratory strains etc.). 579 
This hypothetical case study illustrates how a well-defined AOP could be used for certain 580 
regulatory purposes independent of chemical specific information at the intermediate 581 
key events.  The weight of evidence incorporates over 50 years of research including 582 
basic biochemistry as well as toxicology. Given the strong support and conservation of 583 
the AOP across taxa, a wealth of toxicological data at the organism level can be leveraged 584 
for the decision at hand. This allows the use of in silico predictions for cross-species 585 
extrapolations in combination with use of data from experimentally tractable species to 586 
limit the need for additional studies to characterize intermediate events of well-587 
developed AOPs. If this were not the case, other approaches such as in vitro screening 588 
and in vivo measurement of intermediate KE (Figure S3 in supplementary information) 589 
would likely be required to safeguard against adversely impacting non-target species. 590 
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 591 
6. Implications for Integrated Toxicology and Regulatory Applications  592 
Development and application of AOP-informed IATA represents a new way to evaluate 593 
and generate information to meet different regulatory purposes. A conceptual 594 
framework for applying IATA has been proposed that considers existing information 595 
(from a hazard and exposure perspective) in the context of an AOP to make an informed 596 
decision based on the regulatory context. Frameworks to characterize the scientific 597 
confidence of an AOP that are required to meet different regulatory needs are in 598 
development (Becker et al, 2014; Patlewicz et al., submitted; Perkins et al., submitted). 599 
These will shape the structure of the IATA and its elements in terms of the test methods 600 
and non-testing approaches. Establishing scientific confidence is critical for both the 601 
elements making up the IATA as well as the IATA as a whole. Three case studies have 602 
been described in detail to illustrate how the conceptual framework proposed in Section 603 
1 can be adapted to meet different regulatory purposes (e.g. prioritization, hazard 604 
assessment, classification and labelling and other applications such as cross-species 605 
extrapolations).  606 
The EDC example shows how a battery of AOPs and associated HT assays can be used in 607 
a prioritization scenario. This addresses the first 4 principles for IATA development and 608 
application as outlined in Section 4. The skin sensitization example, which is aimed at 609 
addressing hazard assessment, arguably addresses all 5 principles. The AchE inhibition 610 
example illustrates how an established AOP can be used for classification and labelling in 611 
certain regulatory contexts despite a lack of properly developed testing and non-testing 612 
methods spanning the full AOP continuum. In the regulatory context considered for that 613 
example, the need for explicit tests of intermediate KEs is avoided by the wealth of data 614 
37 
 
available. A well-developed AOP and by demonstration of phylogenetically-conserved 615 
MIEs across taxa enable identification of susceptible species being particularly relevant 616 
or tractable to cost-efficient in vivo testing (e.g. invertebrates). Clearly the degree to 617 
which these principles need to be characterized can and will differ based on the level of 618 
uncertainty that can be tolerated for the regulatory purpose under consideration. 619 
Scientific confidence of the AOP and its associated IATA will be strongest where there is 620 
a close link between the MIE and KEs to the AO.    621 
There is a desire to exploit in silico and HTS testing tools to populate an IATA. One 622 
starting point for such AOP-informed IATAs could be to apply in silico methods or HT 623 
approaches for providing information about the MIE to determine what data if any 624 
would need to be generated for different KEs or the AO for a given chemical. The 625 
stronger the evidence coming from non-testing or alternative testing approaches, the 626 
less additional information would, in theory, need to be generated for a given decision. 627 
Thus, a moderate level of confidence might be sufficient for a prioritization purpose, but 628 
in order to make a decision related to hazard and risk assessment, assays or a 629 
combination of assays closely linked to the MIE and with high predictivity of the AO may 630 
be required (Figure 2). Additional information on one or more KEs along the pathway 631 
generated from in vitro, in chemico or HT/HC assays would serve to provide increasing 632 
confidence for a given decision.   633 
 634 
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Screening Prioritisation Classification & Labelling
Very High
High
Moderate
Limited
Poor
AOP
MIE                  KE                       KE                               AO
Hazard Assessment
Importance of the decision
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 635 
Figure 2. Relationship between strength of evidence (reliability, relevance and concordance 636 
etc.) for the IATA supporting the AO of regulatory concern and the importance of the 637 
regulatory decision to be made. The figure shows the possible combination of AOP based 638 
information and available data, and how the use of one could be strengthened by the other. 639 
The color of the cells represent the amount of additional information from other sources 640 
needed for a decision (the darker the color, the more additional information is needed to 641 
reach a decision with confidence).  642 
 643 
Of course implicit in such a confidence determination, is the WoE evaluation of the AOP 644 
itself. The OECD AOP guidance entails completing a template, using evolved and tailored 645 
Bradford Hill (BH) considerations, in which each KEs and KE relationships (KERs) in an 646 
AOP are evaluated and are scored as high, moderate and low (OECD, 2013). The 647 
outcomes of these WoE determinations for the KEs and KERs of an AOP help in making a 648 
determination of whether different decisions are feasible based on the outcomes of MIEs 649 
or other KEs and the extent to which they are predictive of the AO.  650 
 651 
The case studies presented could in theory be applied in practice now, although the 652 
number of well-developed AOPs is currently limiting the practical applicability for larger 653 
scale regulatory deployment. Furthermore, consideration needs to be given to the 654 
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analytical validation of testing and non-testing approaches in order to better 655 
characterize their applicability domain i.e. the types of chemicals that can be reliably 656 
assessed.  A detailed description of AOPs of regulatory relevance and the establishment 657 
of qualitative and quantitative links between MIEs, KEs and AOs will additionally help 658 
foster application for different regulatory decisions. While qualitative links are already 659 
established for a number of the AOPs so far developed and supported by visualization 660 
and description tools such as the AOP Knowledge Base (https://aopkb.org), appropriate 661 
quantitative approaches for confidence evaluation by WoE assessments of KERs are 662 
currently being critically assessed (Becker et al., in preparation). Recent initiatives to 663 
provide quantitative assessment of the role of MIE and KE proximity to the AO for the 664 
confidence of predictions to regulatory-relevant endpoints will likely also assist in 665 
developing pragmatic tools for IATA development. Additional improvements of IATAs by 666 
including toxicokinetics and reverse dosimetry into extrapolations to regulatory-667 
relevant endpoints would further increase the applicability of IATAs for practical use. 668 
 669 
Although not necessarily applicable to the case studies highlighted here, many of the 670 
AOPs in development have been data-rich and based on historical in vivo data. Thus the 671 
body of evidence to justify the essentiality of KEs and the linkages has facilitated 672 
different use scenarios including risk assessment where the KEs proximal to the AO are 673 
better defined. Going forward, the challenges foreseen will be to identify the data gaps 674 
and assay needs, to integrate different AOPs together to provide a more holistic 675 
assessment of likely effects. The latter is a major issue as an AOP by its nature assumes 676 
that adversity can be described by a relevant assembly of MIEs and KEs, whereas the 677 
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question remains of how many AOPs need to be integrated into IATA to assure that there 678 
is no important hazard or adversity overlooked. 679 
 680 
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